John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, has received a $95,000 sub-award from EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada. The award funds a collaborative study with the University of Alabama at Birmingham (UAB) titled “Effects of Walking Exercise Training on […]Continue Reading ...
A recent article by a team of international experts on multiple sclerosis (MS) underscores the importance of expanding the knowledge base about the hippocampus in order to better understand the genesis of cognitive deficits and develop new treatment strategies. The article, “The hippocampus in multiple sclerosis”, was published in The Lancet Neurology 2018;17:918-926. (doi: 10.1016/S1474-4422(18)30309-0) […]Continue Reading ...
siponimod Treatment for Multiple Sclerosis Novartis Announces FDA and EMA Filing Acceptance of Siponimod for Secondary Progressive Multiple Sclerosis (SPMS) Basel, October 08, 2018 – Novartis today announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company’s New Drug Application (NDA) and Marketing Authorization Application (MAA) […]Continue Reading ...
FRIDAY, Sept. 28, 2018 — Living with a potentially disabling condition like multiple sclerosis (MS) can be difficult, but new research suggests patients get better at dealing with it over time. “There’s an aging paradox in healthy adults. We expect people who are older to be more depressed and anxious because of aging processes [such […]Continue Reading ...
Sep 24 2018 The link between smoking and multiple sclerosis (MS) is “clearer than ever”, the MS Society has announced. Not only are people who smoke more likely to develop MS, smoking can also speed up how fast people with MS become disabled. Ahead of October’s annual ‘Stoptober’ campaign, an independent research review by the […]Continue Reading ...
A recent brief report by MS researchers provides preliminary evidence that older individuals with multiple sclerosis (MS) report lower levels of depression and higher quality of life than their younger counterparts. These findings are consistent with the trend toward improvement in well-being with age in the general population. The article, “Subjective well-being differs with age […]Continue Reading ...
Nancy Chiaravalloti, PhD, and John DeLuca, PhD, have been awarded a $410,000 grant from the Multiple Sclerosis (MS) Society of Canada and the MS Scientific ResearchFoundation to assess the efficacy of a mixed-method intervention to improve cognition in people with progressive MS. This four-year award funds a collaborative study with 11 centers across six countries, […]Continue Reading ...
In multiple sclerosis (MS), not only the T cells of the immune system, but also its B cells, play an important role. This is shown by researchers at Karolinska Institutet and the University of Zurich in a study published in the journal Cell. The findings explain how a new class of MS drugs works, and […]Continue Reading ...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the European launch of Life Effects, a patient-centric website hosting content created by patients and checked by experts, at the European Committee for the Treatment and Research of Multiple Sclerosis (ECTRIMS) Congress in Berlin. This online content initiative was created following extensive research from 13,500 […]Continue Reading ...
Novartis today announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company’s New Drug Application (NDA) and Marketing Authorization Application (MAA) respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis (SPMS) in adults. This phase of multiple sclerosis (MS) can […]Continue Reading ...
Home News Professional Lower Levels of Depression, Higher QOL for Older MS Patients WEDNESDAY, Sept. 26, 2018 — Older individuals with multiple sclerosis (MS) report less severe depressive symptoms and better physical quality of life (QOL), compared to younger patients, according to a brief report recently published in Rehabilitation Psychology. Noting that increased age is […]Continue Reading ...
Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Gilenya® (fingolimod) for the treatment of children and adolescents 10 to 17 years of age with relapsing remitting forms of multiple sclerosis (RRMS). If approved, Gilenya® is expected to be the first oral […]Continue Reading ...
Source: Getty Images In a phase 2 clinical trial, an investigational anti-inflammatory drug called ibudilast was found to be superior to placebo in slowing the progression of brain atrophy in patients with progressive multiple sclerosis. The study, conducted at 28 sites around the country, including Columbia University Irving Medical Center, was published last month in […]Continue Reading ...
LA JOLLA, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the New England Journal of Medicine has published results of the SPRINT-MS Phase 2b trial of MN-166 (ibudilast) in […]Continue Reading ...
A team of researchers the University of Zurich and the University Hospital Zurich has shown that in multiple sclerosis, it is not only specific T cells that cause inflammation and lesions in the brain. B cells, a different type of immune cell, also play a role. These cells activate T cells in the blood. This […]Continue Reading ...
- Cocaine Cut With Anti-Worming Drug, Levamisole, May Cause Brain Damage
- Obese mice lose a third of their fat using a natural protein
- Behind many a Parkinson’s case lurks a mutation in a gene called LRRK2 — why?
- Drug with fish oil cuts risk of heart attack, stroke, study finds
- Mild exposure to single blast can induce meaningful pathogenic effects, study shows
- Miniature pacemakers aim to make heart procedures for infants less invasive, more efficient
- Treating pre-cancerous stem cells at early stage could be key to preventing bowel cancer
- Kawasaki disease triggered by a combination of factors
- Optibrium and University of Nottingham Collaborate on Innovative Teaching Programme
- RNA defects linked to multiple myeloma progression in high risk patients
- Science is on trial – and we need doctors to provide the defense
- Salk researchers receive $19.2 million to unravel mysteries of age-related cognitive decline
- KE Eye Centers offer new solution for patients with myopia and astigmatism
- Trumpeted new Medicare Advantage benefits will be hard for seniors to find
- Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)
- Scientists reveal new cystic fibrosis treatments work best in inflamed airways
- Inexpensive and effective drug does not reduce major adverse cardiovascular event rates
- Testing coronary calcium levels can better predict patient’s risk for coronary heart disease
- FDA conducts mass seizure of food and medical products held under insanitary conditions
- FDA Approves Invokana (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease